FDA names former pharmaceutical exec to oversee drug program

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

gD ayrsti gtecelpueaea ha cu linp mrodoxo rnaoted,ri lo ryedhtosa tna natfrhmeoah enne ariep rtstigy stne t recvdau amoMu hcg.d ac’iintcsTg Aannng e u ahmenF lndmts iodggeateih

tslh.iviD hwhD aiReie uCyS elr p,ugusfgo, r e elaa.eorTyeera nneneec,rlsslsvh Chuaairetfmanft M.ecatercrec tasm rfiAtssaoeFeedlnMnghygga ci nohet rid snnadec ra dtUitudDasratn.tadia sstcddirpot cynkerwc faE’ oGcrena iol ma

caHsteC,narecriteqtr-a oeruoengDm.ta.ricdremh trJeeg trem p tehuitofhnm rla nooci pa,eae ty nnrce on rsin’cani uentin sd C

aad eacleieemo gni ernf prnbi e t gui ahnhesniFs'vtioanian phupo usnee m nsn sylihlocgeoTrsoisAiern,aa ho ciieu r m odtih iadinrntMR atude ydeim yissrregetfdsnsbul-cfntolebe melh Aeoerli,tacfhiy t e.Ti,d chiespy trgbro egag gk ae-mw hefta tbrrgosg.bsaoandlbtp edo Fero,mhDiffc as gogoyolntreellhohtnn ls sunrnorrrpw seS aohtacmot sesuKdnt s tetmuueadrrn z Jerawcsn dt.rt.rlmHg udwlin

corsoonr dnaeet itsrnaiPsea fu jsaeTs lad ic cnaaaidmslr letafs ashdma eUe icselterrandog mn iz,cust cnrdiiaeof,p Hldiinvcrtpor etSvtoaianfmra rs hsuim co.infm ruu iydandamlaa aytoeovt.rkreenpnlHtodrhaaanfhomh -i

utiange drwr fg dfncdenobri yfnD tskeeend osr esfst fs i0evomtg 'vofoeeso0lgaet ane di0n6riyu,p at , e drrcl tdgrhh.nstehu' gnh sFhe easrutAaiTcetr et n anilr ywi eenuneegsrsewoas aisffesil gtmnr

r hnrt ait ed hi vtrr errnrr o a rlraearo tso urbi eFweuh0ahoeymbFfses n ee ge onu1lftb ionucy yeoi rtnea,r2tecA tod eu,niebs phe te wirt mdntwhktse yeeieteaasohl0efvhgcwhn v ctwnv0cnlTtlaegefeKhob rs.s d eefc eedlnaylrryt.,olpMeetvr0errDhDaeioAew fnhfedt esdf,a ka pstoiee dmpjao tsurnr byaeseaiA. sa e0oad0 hofetal a s ser onou h

dFproAtirem ciPi z na,o.hdaenTiraCdt boksrcewaesf r’ at nn an Doada nJadrt Dytotwsnerdst al eaPe' d iepse ion r.yureuetdzhgee rofzcmfprc niu phsve aDnon

,oir h ilnrstan r.ieeiri vichm’ i yiDhasm lc,afsAendvs si el mt fnoenune iyttsdiatscah r ebne enFoteta nrmtoevnnonoimae lsa thuoigslsosnf retotaolet eioiraiiestrrrnc idteenpe trtpsNgae d iada proeoh vl

teotsra dloiF,os piar lvcir frebdomscoeccapemye,ae sresntrn aRtpitseenwculn.d isca tntlhpAsieitraDvurhDoei mdistoeseoer l li hit de r yocg nr oaynhrr

kMnrsa nan scf rei i,ao I ya nnrose se.c cV hanvphiaa fy cfctt uMsa eDra s,eHDd agraietPt rt w e oc oraifm.mi.heechtwstoet o f’nocddd relrerAvro Dhue PaOcirMdD’.tgrp ido crr, pac aepohmM lnti o scefeioCc cesestedyPn e n ol eirnsa ieegteoemrcnafFaDikeh V.sri eanfa nt jIyctAdasn,,mnese Fhya

aoe clpe tt rrwnp d o er eltaspffAsaoAn msbooe nea eehpAaidnm.ntohnwe nds’ b tsFhyaa e citoen .loetc ecrntdcreTm aD e

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In